바이오인

10/30일 오후 1시~6시 성균관대학교 자연과학캠퍼스 삼성 학술정보관 오디토리움

The 3^rd GRL international symposium on RNAi therapeutics

안녕하십니까?
RNAi 신약개발 글로벌연구실 연구책임자 성균관대 이동기 교수 입니다.

1998년 Fire와 Mello가 RNAi 현상을 발견한 이후 생체 내 유전자 발현을 조절하는 핵산 분자를 이용한 신약의 가능성에국내외적으로 폭발적인 관심이 집중되었습니다. 본 RNAi 신약개발 글로벌연구실도 미래창조과학부의 지원으로 2008년부터 RNAi 신약에 응용 가능한 원천기술 개발에 매진하고 있으며, 연구성과들의 기술이전을 통한 치료제 개발이 진행되고 있습니다. 

지난 수년간의 연구 개발을 통해 유전자 조절 핵산 신약 개발의 기술적 난제들이 상당 부분 극복되어, 2013년 Isis사의 고지혈증 치료제인 Kynamro 가 유전자 조절 안티센스 신약으로 FDA 승인을 받았으며, Alnylam 이 개발 중인 유전성 섬유증 치료제가 2017년 경 FDA 승인을 받을 것으로 기대됩니다. 이 외에도 spinal muscular atrophy 와 같은 난치병 치료제에 대한 다양한 유전자 조절 핵산 신약의 임상이 성공적으로 진행되고 있습니다. 이제 유전자 조절 핵산 신약은 더 이상먼 미래의 SF 영화 속 일이 아니라 저분자 화합물과 재조합단백질 이후의 제 3세대 신약 플랫폼으로 자리매김하고 있습니다.

이러한 세계적 추세에 맞추어 이번에 RNAi 신약개발 글로벌 연구실에서는 국내외 학계 및 산업계의 유전자 조절 핵산 신약개발 분야 최고의 전문가를 초청하여 제 3회 국제 심포지움을 개최합니다. 

바쁘시더라도 부디 참석하셔서 우리 앞에 다가온 유전자 조절 핵산 신약 시대에 대해 함께 논의하는 시간을 가지시면 감사하겠습니다.

RNAi 신약개발 글로벌연구실 연구책임자
성균관대학교 화학과 교수 이동기

Muthia Manoharan (Alnylam Pharmaceuticals): Plenary lecture “title to be announced”

Dmitry Samarsky (RiboBio): “RNAi therapeutics: from discovery and delivery to production”

Wes Salomon (U Mass Medical Center; Phil Zamore’s lab): “Argonaute Changes the Rules for Nucleic Acid Hybridization in the miRNA and RNAi pathways”

Thomas Rupp (Thomas Rupp Consulting): “Impurities formed during synthesis & downstream processing of synthetic oligonucleotides”

Chiang Li (Harvard Medical School; Boston Biomedical Inc.) : “title to be announced”

Dong-ki Lee (Sungkyunkwan University): “Therapeutic development using the second generation RNAi triggers”

Sun Woo Hong (OliX Pharmaceuticals): “Development of therapeutics for topically treatable diseases using cell-penetrating asymmetric RNAi triggers”

Young Jik Kwon (UC Irvine): “Nanomedicine for RNAi-mediated synergistic therapy”

Hyung Jun Ahn (KIST): “Rational design and applications of RNA nanoparticles for RNAi-based cancer therapy”

S Sajeesh (Sungkyunkwan University): “Core-Shell Hybrid Nanostructured Delivery Platforms for Advanced RNAi Therapeutics”

Pooja Dua (Sungkyunkwan University): “Theronostic use of SQ2 in Pancreatic cancer: an update on the post Cell-SELEX applications of the aptamer”

Tae Yeon Lee (OliX Pharmaceuticals): “Development of tyrosinase targeting cell penetrating asiRNA (cp-asiRNA) for skin whitening”